|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-2-23
|
|
pubmed:abstractText |
We recently demonstrated that excision repair cross-complementing group 1 protein (ERCC1) is predictive of adjuvant cisplatin-based chemotherapy benefit in resected non-small-cell lung cancer (NSCLC). Non-squamous cell carcinomas (non-SCCs) carry an increased risk of brain metastases (BMs). We hypothesised that there might be an increased incidence of BMs in ERCC1-negative non-SCCs when treated with adjuvant cisplatin-based chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
575-81
|
|
pubmed:meshHeading |
pubmed-meshheading:20801905-Adult,
pubmed-meshheading:20801905-Aged,
pubmed-meshheading:20801905-Antineoplastic Agents,
pubmed-meshheading:20801905-Brain Neoplasms,
pubmed-meshheading:20801905-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:20801905-Chemotherapy, Adjuvant,
pubmed-meshheading:20801905-Cisplatin,
pubmed-meshheading:20801905-Combined Modality Therapy,
pubmed-meshheading:20801905-DNA-Binding Proteins,
pubmed-meshheading:20801905-Endonucleases,
pubmed-meshheading:20801905-Female,
pubmed-meshheading:20801905-Humans,
pubmed-meshheading:20801905-Incidence,
pubmed-meshheading:20801905-Lung Neoplasms,
pubmed-meshheading:20801905-Male,
pubmed-meshheading:20801905-Middle Aged,
pubmed-meshheading:20801905-Multivariate Analysis,
pubmed-meshheading:20801905-Prospective Studies,
pubmed-meshheading:20801905-Randomized Controlled Trials as Topic,
pubmed-meshheading:20801905-Survival Analysis
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy.
|
|
pubmed:affiliation |
Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
